CD19 and hematologic disorder: The effectiveness of CAR therapy is evidenced by the complete eradication of CD19-expressing hematological malignancies following the adoptive transfer of autologous T cells engineered to express a CD19 redirected CAR that is observed in multiple independent trials [4–8].